Lista de obras -

2019 ARIA Care pathways for allergen immunotherapy

artículo científico publicado en 2019

A Randomized Placebo-Controlled Trial of Intradermal Grass Pollen Immunotherapy for Seasonal Allergic Rhinitis

artículo científico publicado en 2016

A randomized, double-blind, placebo-controlled, dose-finding trial with Lolium perenne peptide immunotherapy.

artículo científico publicado en 2017

A randomized, double‐blind, placebo‐controlled trial with mannan‐conjugated birch pollen allergoids

artículo científico publicado en 2023

ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice

artículo científico publicado en 2020

ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines - an EAACI-ARIA position paper

artículo científico publicado en 2020

AllergoOncology: ultra-low IgE, a potential novel biomarker in cancer-a Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI)

artículo científico publicado en 2020

Basophil Activation Test : A diagnostic, predictive and monitoring assay for Allergen Immunotherapy

scientific article published on 09 September 2020

Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper.

artículo científico publicado en 2017

Birch pollen allergen-specific immunotherapy with glutaraldehyde-modified allergoid induces IL-10 secretion and protective antibody responses

scientific article published on 11 April 2019

Cell-free detection of allergen-IgE cross-linking with immobilized phase CD23: inhibition by blocking antibody responses after immunotherapy.

artículo científico publicado en 2013

Deciphering the role of platelets in severe allergy by an integrative omics approach

artículo científico publicado en 2023

Digitally‐enabled, patient‐centred care in rhinitis and asthma multimorbidity: The ARIA‐MASK‐air<sup>®</sup>approach

artículo científico publicado en 2023

EAACI Biologicals Guidelines - Recommendations for severe asthma

scientific article published on 02 June 2020

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma

artículo científico publicado en 2020

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma

artículo científico publicado en 2020

Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma

artículo científico publicado en 2020

Immunology of COVID-19: mechanisms, clinical outcome, diagnostics and perspectives - a report of the European Academy of Allergy and Clinical Immunology (EAACI)

artículo científico publicado en 2020

Immunotherapy in the Clinic

artículo científico publicado en 2024

Improvement of daily allergy control by sublingual immunotherapy: A <scp>MASK</scp>‐air® study

artículo científico publicado en 2023

Intradermal grass pollen immunotherapy increases TH2 and IgE responses and worsens respiratory allergic symptoms

artículo científico publicado en 2016

Is pollen-food syndrome a frequent comorbidity in adults with irritable bowel syndrome?

scientific article published on 30 January 2020

Lipid Transfer Protein allergy in the United Kingdom: Characterization and comparison with a matched Italian cohort

scientific article published on 14 March 2019

Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies

artículo científico publicado en 2011

Mechanisms of Allergen Immunotherapy in Allergic Rhinitis

artículo científico publicado en 2020

Multidimensional endotyping using nasal proteomics predicts molecular phenotypes in the asthmatic airways

artículo científico publicado en 2022

Nasal allergen‐neutralizing antibodies correlate closely with tolerated intranasal allergen challenge dose following grass pollen subcutaneous immunotherapy in patients with local allergic rhinitis

artículo científico publicado en 2024

Patient‐centered digital biomarkers for allergic respiratory diseases and asthma: The <scp>ARIA‐EAACI</scp> approach – ARIA‐EAACI Task Force Report

artículo científico publicado en 2023

Peripheral blood mononuclear cell transcriptome profile in a clinical trial with subcutaneous, grass pollen allergoid immunotherapy

artículo científico publicado en 2024

Perspectives in allergen immunotherapy: 2017 and beyond

artículo científico publicado en 2017

Prioritizing Research Challenges and Funding for Allergy and Asthma and the Need for Translational Research — The European Strategic Forum on Allergic Diseases

artículo científico publicado en 2020

Prioritizing research challenges and funding for allergy and asthma and the need for translational research-The European Strategic Forum on Allergic Diseases

scientific article published on 02 June 2019

Protocol for a double-blind randomised controlled trial of low dose intradermal grass pollen immunotherapy versus a histamine control on symptoms and medication use in adults with seasonal allergic rhinitis (PollenLITE).

artículo científico publicado en 2013

Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses

artículo científico publicado en 2012

Response to Correspondence to “Short‐course subcutaneous treatment with <scp>PQ</scp> Grass strongly improves symptom and medication scores in grass allergy”

artículo científico publicado en 2024

Rhinitis associated with asthma is distinct from rhinitis alone: The <scp>ARIA‐MeDALL</scp> hypothesis

artículo científico publicado en 2023

Short-course of grass allergen peptides immunotherapy over three weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without Asthma: A randomized, multicenter, double-blind, placebo-controlled trial.

artículo científico publicado en 2018

Short‐course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy

artículo científico publicado en 2023

Single-cell RNA sequencing identifies precise tolerogenic cellular and molecular pathways induced by depigmented-polymerized grass pollen allergen extract

artículo científico publicado en 2023

The emerging role of T follicular helper (TFH) cells in aging: influence on the immune frailty

artículo científico publicado en 2020

Vaccines and allergic reactions: The past, the current COVID‐19 pandemic, and future perspectives

scientific article published in 2021

Lista de obras de

2019 ARIA Care pathways for allergen immunotherapy

A Randomized Placebo-Controlled Trial of Intradermal Grass Pollen Immunotherapy for Seasonal Allergic Rhinitis

A randomized, double-blind, placebo-controlled, dose-finding trial with Lolium perenne peptide immunotherapy.

A randomized, double‐blind, placebo‐controlled trial with mannan‐conjugated birch pollen allergoids

ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice

ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines - an EAACI-ARIA position paper

AllergoOncology: ultra-low IgE, a potential novel biomarker in cancer-a Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI)

Basophil Activation Test : A diagnostic, predictive and monitoring assay for Allergen Immunotherapy

Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper.

Birch pollen allergen-specific immunotherapy with glutaraldehyde-modified allergoid induces IL-10 secretion and protective antibody responses

Cell-free detection of allergen-IgE cross-linking with immobilized phase CD23: inhibition by blocking antibody responses after immunotherapy.

Deciphering the role of platelets in severe allergy by an integrative omics approach

Digitally‐enabled, patient‐centred care in rhinitis and asthma multimorbidity: The ARIA‐MASK‐air<sup>®</sup>approach

EAACI Biologicals Guidelines - Recommendations for severe asthma

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma

Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma

Immunology of COVID-19: mechanisms, clinical outcome, diagnostics and perspectives - a report of the European Academy of Allergy and Clinical Immunology (EAACI)

Immunotherapy in the Clinic

Improvement of daily allergy control by sublingual immunotherapy: A <scp>MASK</scp>‐air® study

Intradermal grass pollen immunotherapy increases TH2 and IgE responses and worsens respiratory allergic symptoms

Is pollen-food syndrome a frequent comorbidity in adults with irritable bowel syndrome?

Lipid Transfer Protein allergy in the United Kingdom: Characterization and comparison with a matched Italian cohort

Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies

Mechanisms of Allergen Immunotherapy in Allergic Rhinitis

Multidimensional endotyping using nasal proteomics predicts molecular phenotypes in the asthmatic airways

Nasal allergen‐neutralizing antibodies correlate closely with tolerated intranasal allergen challenge dose following grass pollen subcutaneous immunotherapy in patients with local allergic rhinitis

Patient‐centered digital biomarkers for allergic respiratory diseases and asthma: The <scp>ARIA‐EAACI</scp> approach – ARIA‐EAACI Task Force Report

Peripheral blood mononuclear cell transcriptome profile in a clinical trial with subcutaneous, grass pollen allergoid immunotherapy

Perspectives in allergen immunotherapy: 2017 and beyond

Prioritizing Research Challenges and Funding for Allergy and Asthma and the Need for Translational Research — The European Strategic Forum on Allergic Diseases

Prioritizing research challenges and funding for allergy and asthma and the need for translational research-The European Strategic Forum on Allergic Diseases

Protocol for a double-blind randomised controlled trial of low dose intradermal grass pollen immunotherapy versus a histamine control on symptoms and medication use in adults with seasonal allergic rhinitis (PollenLITE).

Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses

Response to Correspondence to “Short‐course subcutaneous treatment with <scp>PQ</scp> Grass strongly improves symptom and medication scores in grass allergy”

Rhinitis associated with asthma is distinct from rhinitis alone: The <scp>ARIA‐MeDALL</scp> hypothesis

Short-course of grass allergen peptides immunotherapy over three weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without Asthma: A randomized, multicenter, double-blind, placebo-controlled trial.

Short‐course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy

Single-cell RNA sequencing identifies precise tolerogenic cellular and molecular pathways induced by depigmented-polymerized grass pollen allergen extract

The emerging role of T follicular helper (TFH) cells in aging: influence on the immune frailty

Vaccines and allergic reactions: The past, the current COVID‐19 pandemic, and future perspectives